Clinical Research Directory
Browse clinical research sites, groups, and studies.
Natural History Study of Cutaneous Neurofibromas in People With NF1
Sponsor: Johns Hopkins University
Summary
People diagnosed with NF1 may develop cutaneous neurofibromas, also known as cNFs. These benign tumors can cause discomfort and affect a person's quality of life. Researchers at Johns Hopkins are studying how cNF tumors form, grow and change over time. This information may help doctors in the future, provide early interventions and improve quality of life for NF1 patients. Researchers will also explore a new way of monitoring cNF with 3D camera technology. People of all ages with NF1, living in the United States, are invited to participate in this important research study.
Official title: Natural History Study of Cutaneous Neurofibromas in People With Neurofibromatosis Type 1
Key Details
Gender
All
Age Range
1 Year - 100 Years
Study Type
OBSERVATIONAL
Enrollment
500
Start Date
2021-06-28
Completion Date
2029-06-30
Last Updated
2025-10-14
Healthy Volunteers
Not specified
Conditions
Interventions
Evaluation of the natural history of cutaneous neurofibromas
Cutaneous neurofibromas (cNFs) are the most common tumors in people with neurofibromatosis type 1 (NF1). Despite their benign histology, they can significantly impact patients' quality of life (QoL). In this project, the natural history of cNFs will be prospectively and systematically studied. To accomplish this, the reproducibility and efficiency of using 3D whole-body photography was evaluated in a small cohort of patients. The study is enrolling patients of all ages with cNFs into groups by epochs of life to characterize the baseline tumor burden and the change in number and morphology of cNFs over five years. In addition, the study will perform next generation sequencing to describe the genetic variations in the NF1 gene and evaluate potential relations between genotype and phenotype. Lastly, the study will validate clinician- and patient-reported severity scales of cNFs developed for this patient population.
Locations (1)
Johns Hopkins University
Baltimore, Maryland, United States